1. Home
  2. INM vs ACXP Comparison

INM vs ACXP Comparison

Compare INM & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

N/A

Current Price

$1.35

Market Cap

7.1M

Sector

Health Care

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

N/A

Current Price

$1.26

Market Cap

6.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INM
ACXP
Founded
1981
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
6.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
INM
ACXP
Price
$1.35
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
52.7K
★ 79.3K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 62.68
N/A
EPS
N/A
★ N/A
Revenue
★ $4,942,633.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$26.00
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 7.50
N/A
52 Week Low
$0.58
$1.27
52 Week High
$2.50
$8.34

Technical Indicators

Market Signals
Indicator
INM
ACXP
Relative Strength Index (RSI) 44.37 37.98
Support Level $1.25 N/A
Resistance Level $1.40 $1.46
Average True Range (ATR) 0.06 0.05
MACD 0.01 -0.01
Stochastic Oscillator 35.28 31.58

Price Performance

Historical Comparison
INM
ACXP

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: